Consistent findings were observed in the osimertinib subgroup, with a 3-year OS of 62.2% versus 44.6% (<i>P</i> = .03) for low versus high tumor burden.<h4>Conclusion</h4>Tumor burden may serve as a prognostic biomarker in advanced NSCLC receiving EGFR-TKIs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.